Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long‑term open‑label ambrisentan extension in paediatric pulmonary arterial hypertension
2010-021572-29Phase 2Terminated
- Sponsor
- GSK
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ambrisentan in pulmonary arterial hypertension (PAH), sponsored by GSK. Primary endpoint: Primary safety and tolerability of ambrisentan. Started Oct 2010; status: terminated.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2010-021572-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021572-29.